Yamo Pharmaceuticals Tests New Autism Treatment Drug
The FDA-designated drug L1-79 aims to treat core autism symptoms following positive Phase 2 trial results.
Updated on Oct. 28, 2026 in Autism
Live Poll
Should pharmaceutical companies prioritize developing new drug treatments for autism over existing behavioral therapies?
Yamo Pharmaceuticals is developing an investigational oral drug called L1-79 to address core symptoms of autism spectrum disorder. As of June 2026, the company is seeking funding to proceed with late-stage testing of the therapy.
Why it matters
Currently, no medication has received FDA approval to treat the core symptoms of autism. If successful in upcoming trials, L1-79 could become the first therapy specifically designed to address these challenges.
A 12-week Phase 2 study demonstrated improvements in socialization and communication for participants. Yamo Pharmaceuticals now requires $75 million to initiate the necessary Phase 3 clinical trials.
The players
Yamo Pharmaceuticals
This biotechnology company is the developer of the investigational oral therapy L1-79.
FDA
The Food and Drug Administration is the federal agency responsible for regulating medical drugs and approving clinical trial pathways.
The details
The drug L1-79 targets brain signaling pathways to potentially improve social interaction and speech patterns in patients. While it has received fast-track designation from the FDA, access for patients currently remains limited to clinical trials and expanded-access programs.
Timeline
Phase 2 results for the investigational drug were presented in 2025.
A patient began treatment with L1-79 in June 2026.
This report was published in October 2026.
The Big Picture
The development of L1-79 follows the established pattern of the FDA's fast-track designation program designed to expedite the review of drugs for serious conditions. This investigational approach underscores the industry's shift toward targeting neurobiological signaling to address complex behavioral symptoms.
While the drug has shown promise in trials, it is not yet widely available to the public. Patients and families can currently only access the treatment through specific clinical trials or the FDA expanded-access program.
The takeaway
Autism is currently diagnosed in approximately one out of every 31 children, highlighting a significant need for effective therapeutic options. Families interested in emerging treatments should consult with clinical neurologists regarding potential eligibility for ongoing trials.
Further reading
For more context on current research and clinical efforts, visit the Autism section.
Source note: This article includes information reported by Juta MedicalBrief.
Live Poll
Should pharmaceutical companies prioritize developing new drug treatments for autism over existing behavioral therapies?
